 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Journal: The effect of calf subcutaneous fat thickness on patient satisfaction after calf contouring with botulinum toxin A. (Pubmed Central) - Jun 26, 2024
This study identified a U-shaped correlation between calf subcutaneous fat thickness and patient satisfaction rate after treatment. The authors' results provide a theoretical basis for BTXA treatment and suggest the importance of preprocedure conversations in GM hypertrophy treatment.
- | BTXA (lanbotulinumtoxinA) / Sinopharm
Preclinical, Journal: Ultrasound-assisted intravesical botulinum toxin A delivery attenuates acetic acid-induced bladder hyperactivity in rats. (Pubmed Central) - Aug 9, 2023
Ultrasound-assisted intravesical delivery of BTX-A, with the assistance of MB cavitation, led to cleavage of SNAP-25, inhibition of calcitonin gene-related peptide release from afferent nerve terminals, and amelioration of acetic acid-induced bladder hyperactivity. These results support ultrasound-assisted intravesical delivery as an efficient non-injection method for administering BTX-A.
- || BTXA (lanbotulinumtoxinA) / Sinopharm
Review, Journal: Chinese botulinum toxin A for the treatment of lower urinary tract dysfunction: It works just as well. (Pubmed Central) - Nov 26, 2022
Our experience showed that Chinese BoNT/A was as good as other BoNT/A products in terms of efficacy, safety, and tolerability. In this study, we explored the current and potential applications of Chinese BoNT/A in urology, and reviewed the background information regarding the toxin.
- | BTXA (lanbotulinumtoxinA) / Sinopharm
Journal: A new paradigm of sewage collection in rural areas. (Pubmed Central) - Nov 20, 2022
The q is used to create the best possible pipe network layout, determine the appropriate treatment method, and reduce construction costs. This model can be widely applied to sewage collection in rural areas of China, where the overall sewage collection system can implement different regional strategies to maximize rural pollution control and protect the environment.
- || BTXA (lanbotulinumtoxinA) / Sinopharm
Clinical, Journal: Hengli Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. (Pubmed Central) - Mar 8, 2022
Hengli BTX-A treatment was well-tolerated and resulted in significant improvements in OAB symptoms among Chinese patients inadequately managed by anticholinergics. Clinical Trial Registration: http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, Identifier: CTR20131190.
- || BTXA (lanbotulinumtoxinA) / Sinopharm
PetroChina, Hengli win four cargoes in first China oil reserve sale https://t.co/1wPq0yaIFb (Twitter) - Sep 24, 2021
- || BTXA (lanbotulinumtoxinA) / Sinopharm
Review, Journal: Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review. (Pubmed Central) - Jul 7, 2021
LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America.
- |||| BTXA (lanbotulinumtoxinA) / Sinopharm
Trial primary completion date: A Study to Evaluate Botulinum Toxin Type A for Injection?HengLi (clinicaltrials.gov) - Jan 3, 2018
P3, N=288, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America. Trial primary completion date: Dec 2018 --> Dec 2019
- |||| BTXA (lanbotulinumtoxinA) / Sinopharm
Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) (clinicaltrials.gov) - Jan 3, 2018
P3, N=216, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jul 2017 --> Nov 2018
- ||||||| BTXA (lanbotulinumtoxinA) / Sinopharm
Trial completion, Trial primary completion date: A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity (clinicaltrials.gov) - Sep 26, 2016
P3, N=180, Completed, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Trial primary completion date: Jul 2017 --> Nov 2018 Enrolling by invitation --> Completed | Trial primary completion date: Nov 2015 --> Feb 2016
- |||| BTXA (lanbotulinumtoxinA) / Sinopharm
Trial primary completion date: A Study to Evaluate Botulinum Toxin Type A for Injection?HengLi (clinicaltrials.gov) - Sep 26, 2016
P3, N=288, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Enrolling by invitation --> Completed | Trial primary completion date: Nov 2015 --> Feb 2016 Trial primary completion date: Oct 2016 --> Dec 2018
- |||||||||| BTXA (lanbotulinumtoxinA) / Sinopharm
New P3 trial: A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) (clinicaltrials.gov) - Jun 1, 2016
P3, N=216, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
- | BTXA (lanbotulinumtoxinA) / Sinopharm
Enrollment open: A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity (clinicaltrials.gov) - Dec 30, 2014
P3, N=180, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Trial primary completion date: Oct 2016 --> Dec 2018 Active, not recruiting --> Enrolling by invitation
- | BTXA (lanbotulinumtoxinA) / Sinopharm
Enrollment open: A Study to Evaluate Botulinum Toxin Type A for Injection?HengLi (clinicaltrials.gov) - Dec 30, 2014
P3, N=288, Enrolling by invitation, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Active, not recruiting --> Enrolling by invitation Active, not recruiting --> Enrolling by invitation
- || BTXA (lanbotulinumtoxinA) / Sinopharm
New P3 trial: A Study to Evaluate Botulinum Toxin Type A for Injection?HengLi (clinicaltrials.gov) - Nov 14, 2014
P3, N=288, Active, not recruiting, Sponsor: Lanzhou Institute of Biological Products Co., Ltd
- || BTXA (lanbotulinumtoxinA) / Sinopharm
New P3 trial: A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity (clinicaltrials.gov) - Oct 31, 2014
P3, N=180, Active, not recruiting, Sponsor: Lanzhou Institute of Biological Products Co., Ltd